Besides KRAS and TP53 hotspot mutations, we identified KIT, EGFR, PIK3CA, c-MET, BRAF, STK11, ATM, CDKN2A, and APC hotspot mutations and/or gene variants in more than 5% of patients with metastatic NSCLC as shown in Table 2. This evidence concerns the gene MET and non-small cell lung carcinoma.